Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast
February 28 2020 - 8:30AM
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that
Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm,
is scheduled to make a webcast presentation at the Barclays Global
Healthcare Conference in Miami on Wednesday, March 11, 2020, at
2:35 p.m. ET.
To access the live webcast of the presentation,
or the subsequent archived recording, please visit the “Investors”
section of the Ziopharm website at www.ziopharm.com.
About Ziopharm Oncology, Inc.
Ziopharm Oncology is an immuno-oncology company focused on
developing end-to-end cost-effective solutions using its non-viral
Sleeping Beauty platform for T-cell receptor (TCR) and chimeric
antigen receptor (CAR) T-cell therapies and immune-stimulating gene
therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty
platform genetically modifies T cells with DNA plasmids to express
TCRs to target neoantigens inside and outside hotspots for solid
tumors and CAR to target CD19 for blood cancers using the Company’s
“Rapid Personalized Manufacturing” to produce and release CAR-T as
soon as the day after gene transfer. The Sleeping Beauty platform
is being advanced in collaboration with the National Cancer
Institute, The University of Texas MD Anderson Cancer Center and
Eden BioCell. The Company is also developing its Controlled IL-12
platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in
combination with immune checkpoint inhibitors to treat brain
cancer, including in collaboration with Regeneron
Pharmaceuticals.
Contact for Ziopharm Oncology: Chris Taylor VP,
Investor Relations and Corporate Communications T: 617-502-1881 E:
ctaylor@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024